Skye Bioscience, Inc.
SKYE
$1.91
$0.094.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -150.02% | 50.67% | -57.44% | -13.57% | 82.28% |
| Total Depreciation and Amortization | 165.61% | 121.48% | 7.97% | -2.82% | -1.39% |
| Total Amortization of Deferred Charges | -100.00% | -55.45% | 5.52% | 4.26% | 122.17% |
| Total Other Non-Cash Items | 186.38% | -225.89% | 56.44% | 210.07% | -97.99% |
| Change in Net Operating Assets | -180.26% | 169.61% | -20.97% | -1,063.11% | 81.32% |
| Cash from Operations | -55.30% | 25.81% | -50.67% | -22.46% | 5.18% |
| Capital Expenditure | 96.71% | -4,572.00% | -915.63% | 54.29% | -89.19% |
| Sale of Property, Plant, and Equipment | 92.86% | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 106.25% | -4,347.69% | -102.85% | 16,414.29% | -100.65% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | 66.62% |
| Issuance of Common Stock | -- | -- | -- | 32,209.54% | -97.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -4,318.33% |
| Cash from Financing | -- | 100.00% | -102.45% | 377,424.23% | -100.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -20.41% | 27.26% | -111.23% | 2,218.69% | -128.38% |